• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.

作者信息

Torisu M, Katano M, Kimura Y, Itoh H, Takesue M

出版信息

Surgery. 1983 Mar;93(3):357-64.

PMID:6187080
Abstract
摘要

相似文献

1
New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.用链球菌制剂OK-432治疗恶性腹水的新方法。I. 宿主免疫力的改善和生存期的延长。
Surgery. 1983 Mar;93(3):357-64.
2
New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction.用链球菌制剂OK-432治疗恶性腹水的新方法。II. 腹膜内炎症细胞介导的肿瘤细胞破坏。
Surgery. 1983 Mar;93(3):365-73.
3
[Treatment of malignant ascites. II. Immunological studies on disappearance of ascites by intraperitoneal injection of a streptococcal preparation, OK-432 (author's transl)].恶性腹水的治疗。II. 关于腹腔注射链球菌制剂OK-432导致腹水消失的免疫学研究（作者译）
Fukuoka Igaku Zasshi. 1981 Oct;72(10):543-55.
4
Immunological parameters in gastric cancer patients treated with immunotherapy of streptococcal preparation OK-432.接受链球菌制剂OK-432免疫治疗的胃癌患者的免疫学参数
Keio J Med. 1982 Dec;31(4):159-68. doi: 10.2302/kjm.31.159.
5
Malignant ascites treated with streptococcal extract.用链球菌提取物治疗恶性腹水。
Lancet. 1983 Jun 4;1(8336):1258.
6
[The management of malignant ascites with a streptococcal preparation, OK-432: relation between the clinical effect and auto-tumor cell killing activity by OK-432-induced ascites-derived lymphocytes].[用链球菌制剂OK-432治疗恶性腹水：OK-432诱导的腹水来源淋巴细胞的临床疗效与自身肿瘤细胞杀伤活性之间的关系]
Gan To Kagaku Ryoho. 1987 Aug;14(8):2464-8.
7
[Management of malignant ascites with a streptococcal preparation, OK-432: induction of growth inhibition factor(s) against tumor cells].用链球菌制剂OK-432治疗恶性腹水：诱导针对肿瘤细胞的生长抑制因子
Nihon Geka Gakkai Zasshi. 1986 Apr;87(4):471.
8
[Non-specific immunotherapy with OK-432, streptococcus pyogenes preparation, for inoperable cancer patients of the digestive tract].[用链球菌制剂OK-432对无法手术的消化道癌症患者进行非特异性免疫治疗]
Nihon Gan Chiryo Gakkai Shi. 1984 Jul 20;19(6):1307-14.
9
New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.用链球菌制剂OK-432治疗恶性腹水的新方法。III. OK-432通过活化中性粒细胞释放的趋化因子吸引自然杀伤细胞。
Surgery. 1990 Jan;107(1):74-84.
10
[Postoperative cell-mediated immunity in gastric cancer patients--with special reference to the effects of immunotherapy].胃癌患者术后的细胞介导免疫——特别提及免疫治疗的效果
Gan No Rinsho. 1985 Sep;31(11):1381-6.

引用本文的文献

1
Contemporary Management of Malignant Ascites.恶性腹水的当代管理
J Surg Res. 2025 Mar;307:157-175. doi: 10.1016/j.jss.2025.01.025. Epub 2025 Mar 3.
2
Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response.卵巢癌中的恶性腹水：分子特征和治疗反应的细胞、无细胞及生物物理决定因素
Cancers (Basel). 2021 Aug 26;13(17):4318. doi: 10.3390/cancers13174318.
3
Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity.
OK-432 诱导的干扰素-α诱导树突状细胞成熟后具有 TRAIL 和 Fas 配体通路介导的杀伤活性。
Sci Rep. 2017 Feb 13;7:42145. doi: 10.1038/srep42145.
4
Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.腹腔内化疗治疗腹膜表面恶性肿瘤：1000 例患者的经验。
J Am Coll Surg. 2014 Apr;218(4):573-85. doi: 10.1016/j.jamcollsurg.2013.12.013. Epub 2013 Dec 21.
5
Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.溶瘤病毒治疗肺癌皮下移植瘤模型中恶性积液的疗效观察。
J Transl Med. 2013 May 1;11:106. doi: 10.1186/1479-5876-11-106.
6
Malignant ascites: pathophysiology and treatment.恶性腹水：病理生理学与治疗。
Int J Clin Oncol. 2013 Feb;18(1):1-9. doi: 10.1007/s10147-012-0396-6. Epub 2012 Mar 31.
7
Treatment of malignant ascites.恶性腹水的治疗
Curr Treat Options Oncol. 2008 Jun;9(2-3):215-33. doi: 10.1007/s11864-008-0068-y. Epub 2008 Sep 6.
8
Prognostic significance of peritoneal lavage cytology in gastric cancer in Singapore.新加坡胃癌患者腹腔灌洗细胞学检查的预后意义
Gastric Cancer. 2005;8(4):228-37. doi: 10.1007/s10120-005-0343-6.
9
Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion.多机构随机临床研究：腔内化疗单独治疗、免疫治疗单独治疗与免疫化疗治疗恶性胸腔积液的疗效比较
Br J Cancer. 1999 May;80(5-6):775-85. doi: 10.1038/sj.bjc.6690421.
10
Cytokine-mediated antitumor effect of OK-432 on urinary bladder tumor cells in vitro.OK-432对膀胱肿瘤细胞的细胞因子介导的体外抗肿瘤作用。
Urol Res. 1997;25(4):239-45. doi: 10.1007/BF00942092.